aTyr Pharma, Inc. (NASDAQ:LIFE) has analysts on the Bullish side this week.

February 20, 2018 - By Michael Collier

 aTyr Pharma, Inc. (NASDAQ:LIFE) has analysts on the Bullish side this week.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Among 7 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 have Buy rating, 3 Sell and 3 Hold. Therefore 14% are positive. Life Technologies Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. As per Thursday, September 17, the company rating was downgraded by Zacks. The company was downgraded on Wednesday, February 14 by JP Morgan. The stock has “Hold” rating by BMO Capital Markets on Monday, August 14. As per Tuesday, August 25, the company rating was downgraded by Zacks. The stock has “Market Perform” rating by William Blair on Thursday, March 31. Citigroup maintained aTyr Pharma, Inc. (NASDAQ:LIFE) rating on Tuesday, August 16. Citigroup has “Neutral” rating and $4 target. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Buy” rating by Piper Jaffray on Thursday, September 7. JP Morgan maintained it with “Overweight” rating and $10 target in Thursday, August 11 report. The rating was initiated by Citigroup with “Neutral” on Wednesday, December 16. The stock has “Sell” rating by J.P. Morgan on Wednesday, February 14. Below is a list of aTyr Pharma, Inc. (NASDAQ:LIFE) latest ratings and price target changes.

14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
14/11/2017 Broker: J.P. Morgan Rating: Hold
01/11/2017 Broker: BMO Capital Markets Rating: Hold New Target: $4.0 Maintain
07/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $7.0 Initiate

The stock increased 1.59% or $0.05 during the last trading session, reaching $3.2. About 2,049 shares traded. aTyr Pharma, Inc. (NASDAQ:LIFE) has risen 12.96% since February 20, 2017 and is uptrending. It has underperformed by 3.74% the S&P500.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $95.23 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: which released: “aTyr Pharma Enters into $20 Million Credit Facility” on November 21, 2016, also with their article: “aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors” published on April 03, 2017, published: “aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference” on May 31, 2017. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: and their article: “aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J …” published on September 21, 2016 as well as‘s news article titled: “aTyr Pharma Appoints Sanjay Shukla, MD, MS, as Chief Medical Officer” with publication date: March 30, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: